Retatrutide vs Tirzepatide: What the Trials Actually Show

By Evan Marsh, EditorUpdated August 7, 2026Phase 2/3 trial data, matched estimand for estimand

This comparison is made constantly and almost always made wrong, because the two drugs' results are reported using different analyses, at different time points, in separate trials that never enrolled the same people. Below is the honest version: matched analyses where matching is possible, and an explicit note wherever it is not.

The short answer

Retatrutide reported larger weight reductions. Tirzepatide is approved, prescribable, covered by insurance in many cases, and backed by years of real-world safety data. There has never been a head-to-head trial. If the question is "which produced bigger numbers in its own trial," retatrutide. If it is "which can a person actually obtain and use under medical supervision," tirzepatide, and it is not close.

Side by side

	Retatrutide	Tirzepatide
Receptor targets	GIP + GLP-1 + glucagon	GIP + GLP-1
Development code	LY3437943	LY3298176
Status	Phase 3; BLA submission stated for Q1 2027	FDA approved (Zepbound, Mounjaro)
Pivotal obesity trial	TRIUMPH-1, n=2,339, 80 weeks	SURMOUNT-1, n=2,539, 72 weeks
Weight change, counting everyone randomized	−25.0%	−20.9%
Weight change, assuming full adherence	−28.3%	Reported separately in SURMOUNT-1
Peer-reviewed?	Phase 2 yes; Phase 3 topline only	Yes — NEJM 2022
Dosing	2–12 mg weekly in trials	2.5–15 mg weekly per label
Other approved indications	None	Obstructive sleep apnea in adults with obesity; type 2 diabetes as Mounjaro
Can a doctor prescribe it?	No	Yes

Mean body-weight reduction, counting every participant randomised

InvestigationalFDA approved

Retatrutide 12 mgTRIUMPH-1, 80 weeks

25.0%

Tirzepatide 15 mgSURMOUNT-1, 72 weeks

20.9%

Why this chart uses 25.0% and not 28.3%. Obesity trials report every result twice: once counting all randomized participants regardless of whether they stayed on the drug, and once assuming everyone adhered. Lilly calls these treatment-regimen and efficacy; Novo Nordisk calls the same two things treatment policy and trial product. The gap between conventions runs 1.6 to 3.6 percentage points — larger than the difference between some neighbouring drugs. Retatrutide's famous 28.3% is the adherence-assuming figure; placing it beside SURMOUNT-1's count-everyone number would hand it two to three free points. Both bars above use the same convention.

The comparison the numbers still cannot make

Even matched estimand for estimand, three problems remain:

Different trial lengths. 80 weeks versus 72. Weight curves in both programs were still descending at the end, so extra weeks favour retatrutide for reasons unrelated to the molecule.
Different populations. Separate trials, separate enrollment criteria, separate sites and eras. Cross-trial comparison is an estimate, not a measurement.
Different evidence tiers. SURMOUNT-1 is peer-reviewed in the New England Journal of Medicine. The TRIUMPH Phase 3 results are company topline announcements and conference presentations, which is a weaker tier and can change on the way to publication.

A head-to-head trial would settle it. None has been run.

Mechanism: what the third receptor adds

GLP-1 and GIP activity work largely through appetite and satiety — they make eating less feel manageable. Adding glucagon receptor agonism does something different: it increases energy expenditure and mobilizes fat from the liver. That is a second mechanism rather than a stronger version of the first, and it is the pharmacological argument for why retatrutide's numbers are higher. It is also why its trials watched heart rate and liver enzymes more closely, and why a Phase 2a trial reported large reductions in liver fat.

Side effects and tolerability

Both drugs are dominated by gastrointestinal effects concentrated during dose escalation. In the retatrutide Phase 3 program, diarrhea rather than nausea was the most common complaint, and a dose-related dysesthesia signal appeared that has no counterpart in the tirzepatide label. Tirzepatide's label carries the class boxed warning for thyroid C-cell tumors seen in rodents, along with the standard pancreatitis and gallbladder cautions.

The asymmetry that matters most is not in the adverse-event tables: tirzepatide has been in approved clinical use for years, generating post-marketing safety data across a far larger and less selected population than any trial. Retatrutide's safety record ends where its trials end. Full detail on theretatrutide side effects page.

Practical difference

Tirzepatide can be prescribed, dispensed by a pharmacy, monitored by a clinician and in many cases partly covered by insurance, with manufacturer savings programs bringing real-world cost below list price. Retatrutide cannot be prescribed at all, cannot be legally compounded, and everything sold online is unregulated research-grade material. That gap is the actual decision most readers face — ouraccess and approval timeline page covers the legitimate routes, and thesupplier comparison covers sourcing for those who go the research route anyway.

Frequently asked questions

Is retatrutide better than tirzepatide?

On reported weight reduction the retatrutide numbers are larger, but no head-to-head trial has ever compared them, the trials ran for different lengths, and only tirzepatide can actually be prescribed. "Larger numbers in separate trials" and "better drug" are different claims.

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide adds a third, glucagon, which increases energy expenditure and mobilizes liver fat rather than working only through appetite. Tirzepatide is FDA approved as Zepbound and Mounjaro; retatrutide is in Phase 3 with no approval.

How much more weight do people lose on retatrutide vs tirzepatide?

Comparing like with like — the analysis that counts every randomized participant — retatrutide reported 25.0% at 80 weeks in TRIUMPH-1 and tirzepatide 20.9% at 72 weeks in SURMOUNT-1. That is roughly a four-point gap, but eight of those extra weeks belong to retatrutide's longer trial, not to the molecule.

Can I get retatrutide instead of tirzepatide?

Not through a prescription. Tirzepatide has an approved label, a pharmacy pathway and manufacturer savings programs. Retatrutide has no approval, no legal compounding route, and the only supervised access is a clinical trial.

Which has worse side effects?

Both are dominated by gastrointestinal effects that are worst during dose escalation. Retatrutide trials additionally tracked heart rate and a dose-related dysesthesia signal, and its glucagon component is why liver enzymes were monitored more closely. Tirzepatide has a far larger safety database simply because it has been in approved use for years.

Sources

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387(3):205–216. PubMed
Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023;389(6):514–526. PubMed
Eli Lilly. TRIUMPH-1 topline results, 21 May 2026. Company announcement. Not peer-reviewed.
Giblin K et al. Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism, 2026;28(1):83–93. PubMed
ZEPBOUND (tirzepatide) prescribing information. DailyMed label
Registry records: TRIUMPH-1 (NCT05929066).

Related guides

Research use only. Retatrutide is investigational and not approved for human use. This page compares published trial data and is not medical advice; decisions about approved medicines belong with a physician.